All In Biotech

NDA 208901 · Mayne Pharma

Tolsura

Itraconazole · Oral · Azole Antifungal

Last checked: Nov 20, 2026Latest source record: Oct 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Dec 11, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

507

27 Phase 3, 40 recruiting

FAERS reports

9,411

8,437 serious, 1,977 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CONGESTIVE HEART FAILURE and DRUG INTERACTIONS WARNING: CONGESTIVE HEART FAILURE and DRUG INTERACTIONS See full prescribing information for complete boxed warning. Congestive Heart Failure TOLSURA can cause or exacerbate congestive heart failure (CHF). When itraconazole was administered intravenously to healthy human volunteers and dogs, negative inotropic effects were seen. If signs or symptoms of congestive heart failure occur or worsen during administration of TOLSURA, reassess the benefit-risk of continuing treatment. ( 5.1 , 6 ). Drug Interactions Co-administration of certain drugs that are metabolized by human CYP3A4 enzymes are contraindicated with TOLSURA because plasma concentrations of such drugs are increased. ( 4.1 , 5.5 , 7.1 ) Co-administration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic...

What it is approved for

From the label in effect Apr 23, 2025.

TOLSURA is indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised adult patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-fungal therapy should be adjusted accordingly TOLSURA is an azole antifungal indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised adult patients ( 1 ): Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Limitations of Use: TOLSURA is not indicated for the treatment of onychomycosis ( 1 ) TOLSURA is NOT interchangeable or substitutable with other itraconazole products ( 1 ) Limitations of Use: TOLSURA is not indicated for the treatment of onychomycosis. TOLSURA is NOT interchangeable or substitutable with other itraconazole products due to the differences in the dosing between TOLSURA and other itraconazole products. Therefore, follow the specific dosage recommendations for TOLSURA [see Dosage and Administration (2) ].

Mechanism: Itraconazole is an azole antifungal drug [see Microbiology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 11, 2018 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • TOLSURA · ITRACONAZOLE 65MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Itraconazole" as an intervention, any sponsor and status, largest first.

All 507 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,040
  • drug interaction1,022
  • off label use518
  • pyrexia494
  • pneumonia412
  • febrile neutropenia341
  • nausea334
  • dyspnoea333
  • condition aggravated320
  • diarrhoea304
  • neutropenia276
  • anaemia251

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004146
200596
2006146
2007189
2008208
2009288
2010250
2011555
2012464
2013312
2014286
2015446
2016341
2017431
2018589
2019661
2020712
2021659
2022538
2023569
2024524
2025527
2026473

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tolsura (Itraconazole)

2024 spending

$559K

Beneficiaries

43

195 claims

Per beneficiary

$13,007

$37.49 per unit

View as table
YearSpending
2020$502,137
2021$902,242
2022$1,294,835
2023$769,425
2024$559,317

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 970 on PubMed

Sponsor: Mayne Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.